Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  DiaMedica Inc.    DMA   CA25253T1075

News SummaryMost relevantAll newsSector newsTweets

DiaMedica : Issues Stock Option Grant

share with twitter share with LinkedIn share with facebook
share via e-mail
06/20/2017 | 12:31am CEST

MINNEAPOLIS, June 19, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces that the Board of Directors has granted options to purchase 1,775,000 common shares of the Corporation to the Company's management and board of directors at an exercise price of $0.32 per share. These options were awarded in accordance with the Company's stock option plan for a ten-year term.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica's shares are listed on the TSX Venture Exchange under the trading symbol "DMA" and on the OTCQB under the trading symbol "DMCAF". For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn


The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the DiaMedica's filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.


Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Phone: (617) 899-5941

Source: DiaMedica

2017 GlobeNewswire, Inc., source Press Releases - Canada

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DIAMEDICA INC.
09/11 DIAMEDICA : Announces the Initiation of Phase 2 Trial Evaluating DM199 (Recombin..
06/20 DIAMEDICA : Issues Stock Option Grant
05/01 DIAMEDICA THERAPEUTICS : Announces Recently Granted Formulation Patent in U.S. f..
05/01 DIAMEDICA : Announces Recently Granted Formulation Patent in U.S. for DM199
04/25 DIAMEDICA THERAPEUTICS : Announces Dr. Nancy Chang to its Strategic Advisory Boa..
04/20 DIAMEDICA : Patent Issued for Formulations of Human Tissue Kallikrein-1 for Pare..
04/18 DIAMEDICA THERAPEUTICS : Completes Private Placement With U.S. Based Family Offi..
04/18 DIAMEDICA : Therapeutics Completes Private Placement With U.S. Based Family Offi..
03/20 DIAMEDICA THERAPEUTICS : Announces Issuance of European Composition of Matter Pa..
03/20 DIAMEDICA : Announces Issuance of European Composition of Matter Patent and Addi..
More news
News from SeekingAlpha
2016 WEEK IN REVIEW : Cross-Border Investments Rule The News
Rick John Pauls President, Chief Executive Officer & Director
Richard Dal Pilnik Chairman
David A. Gurvey Vice President-Finance
Todd A. Verdoorn Chief Scientific Officer
Michael R. Giuffre Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297